簡介:酒石酸卡巴拉汀,Rivastigmine酒石酸鹽是膽堿酯酶抑制劑,IC50為5.5 uM,還能抑制丁酰膽堿酯酶和乙酰膽堿酯酶。
酒石酸卡巴拉汀物理化學性質:
沸點 |
316.2oC at 760 mmHg |
熔點 |
123-1250C |
分子式 |
C18H28N2O8 |
分子量 |
400.423 |
閃點 |
145oC |
精確質量 |
400.18457 |
PSA |
147.84 |
LogP |
0.6371 |
外觀性狀 |
白色至灰白色粉末 |
蒸汽壓 |
0.000416mmHg at 25°C |
儲存條件 |
-20°C Freezer |
水溶解性 |
可溶于:甲醇 |
酒石酸卡巴拉汀詳細介紹:
中文名稱: |
酒石酸卡巴拉汀 |
中文別名: |
酒石酸卡巴拉汀;(S)-N-乙基-N-甲基氨基甲酸-3-[(1-二甲氨基)乙基]苯酯酒石酸鹽;卡巴拉汀或利斯的明酒石酸鹽;L-酒石酸卡巴拉汀;2,3',4-三溴二苯醚;N-乙基甲基氨基甲酰氯;Rivastigmine L-Tartrate L-酒石酸卡巴拉汀;酒石酸卡巴拉汀 USP標準品;酒石酸卡巴拉汀Rivastigmine tartrate;酒石酸卡巴拉汀標準品;酒石酸卡巴拉汀氫 EP標準品;酒石酸利凡斯的明;卡巴拉丁;卡巴拉汀酒石酸鹽;重酒石酸卡巴拉汀;重酒石酸利凡斯的明;(S)-N-乙基-N-甲基氨基甲酸-3-[(S)-1-(二甲氨基)乙基]苯酯酒石酸鹽;氘代重酒石酸利斯的明-d6;酒石酸卡巴拉汀 中文別名:卡巴拉汀或利斯的明酒石酸鹽;酒石酸利伐斯的明;酒石酸利瓦斯汀;利斯的明酒石酸鹽;卡巴拉汀重酒石酸鹽 |
英文名稱: |
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R,3R)-2,3-dihydroxysuccinate |
英文別名: |
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R,3R)-2,3-dihydroxysuccinate;RIVASTIGMINE TARTRATE SALT;SDZ-ENA 713;Ethylmethyl-carbamic Acid 3-[(1S)-1-(Dimethylamino)ethyl]phenyl Ester, Bitartrate;(S)-N-Ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenylcarbamate hydrogen tartrate;Rivastigmine-d6 tartarate;Rivastigmine Tartrate;Rivastigmine (tartrate);Rivastigmine Hydrogen Tartrate;Rivastigmine Tartrat;3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate;ENA 713;N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate;Rivastigmine;RivastigMine L-Tartrate;ENA-713;Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester;N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate;S-Rivastigmine tartrate;Rivastigimine tartrate;rivastigMine ditartrate;RivastigMine Bitartrate |
CAS號: |
129101-54-8 |
分子式: |
C14H22N2O2.C4H6O6 |
分子量: |
400.42 |
詳細描述: |
博飛美科提供129101-54-8,酒石酸卡巴拉汀,Rivastigmine Tartrate,Perfemiker,上海現(xiàn)貨。 Perfemiker,致力于提供高品質、高性價比小分子化合物的產(chǎn)品。 Perfemiker小分子化合物大量庫存,提供超過2萬種的抑制劑、激動劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應商。 AChR抑制劑,Rivastigmine酒石酸鹽是膽堿酯酶抑制劑,IC50為5.5 uM,還能抑制丁酰膽堿酯酶和乙酰膽堿酯酶。 查詢關鍵詞:“129101-54-8,酒石酸卡巴拉汀,Rivastigmine Tartrate,Perfemiker,上?,F(xiàn)貨”。 |
酒石酸卡巴拉汀參考文獻:
[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.
[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.
[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.
[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.